ReviewLife (Basel, Switzerland)2021
Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Severe Neurocognitive Manifestations in Healthy Young Individuals With COVID-19: A Case Series.Clinical medicine insights. Case reports · 2025Article
- Omics-based analysis of mitochondrial dysfunction and BBB integrity in post-COVID-19 sequelae.Scientific reports · 2024Article
- Coronavirus disease 2019 and its impact on the cognition of older adults: Unraveling the role of inflammation.Comprehensive psychoneuroendocrinology · 2024Article
- The Interplay between Gender and Duration of Hospitalization Modulates Psychiatric Symptom Severity in Subjects with Long COVID-19.Brain sciences · 2024Article
- Cognitive disengagement syndrome in pediatric patients with long COVID: associations with mood, anxiety, and functional impairment.Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence · 2024Article
- Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Synthesis of anti-depressant moleculesRSC advances · 2024Review
- The Effect of Antidepressant Treatment on Neurocognitive Functions, Redox and Inflammatory Parameters in the Context of COVID-19.Journal of clinical medicine · 2023Article
- Antidepressant Activities of Synthesized Benzodiazepine Analogues in Mice.Brain sciences · 2023Article
- Clinical-Immunological Correlates in Post-COVID-19 Endogenous Psychoses.Neuroscience and behavioral physiology · 2023Article
- Is SARS-CoV-2 a Risk Factor of Bipolar Disorder?-A Narrative Review.Journal of clinical medicine · 2022Review
- Long COVID and neuropsychiatric manifestations (Review).Experimental and therapeutic medicine · 2022Review
- Review
- Article
- Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.International journal of molecular sciences · 2022Review
- Determinants of Stress Levels and Behavioral Reactions in Individuals With Affective or Anxiety Disorders During the COVID-19 Pandemic in Russia.Frontiers in sociology · 2022Article
- Mapping the structure of depression biomarker research: A bibliometric analysis.Frontiers in psychiatry · 2022Article
- Treatment paradigms in Parkinson's Disease and Covid-19.International review of neurobiology · 2022Article
- Brain microstructural changes and fatigue after COVID-19.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The dysfunctional effects of the coronavirus disease 2019 (COVID-19) infection on the nervous system are established. The manifestation of neuropsychiatric symptoms during and after infection is influenced by the neuroinvasive and neurotrophic properties of SARS-CoV-2 as well as strong inflammation characterised by a specific "cytokine storm". Research suggests that a strong immune response to a SARS-CoV-2 infection and psychological stressors related to the pandemic may cause chronic inflammatory processes in the body with elevated levels of inflammatory markers contributing to the intensification of neurodegenerative processes. It is suggested that neuroinflammation and associated central nervous system changes may significantly contribute to the etiopathogenesis of depressive disorders. In addition, symptoms after a COVID-19 infection may persist for up to several weeks after an acute infection as a post-COVID-19 syndrome. Moreover, previous knowledge indicates that among SSRI (selective serotonin reuptake inhibitor) group antidepressants, fluoxetine is a promising drug against COVID-19. In conclusion, further research, observation and broadening of the knowledge of the pathomechanism of a SARS-CoV-2 infection and the impact on potential complications are necessary. It is essential to continue research in order to assess the long-term neuropsychiatric effects in COVID-19 patients and to find new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.